Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
84.6 CHF | -0.29% | -1.18% | -0.29% |
Apr. 17 | Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years | MT |
Apr. 17 | Novartis: positive efficacy data in MS | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.29% | 204B | |
+28.79% | 676B | |
+25.43% | 554B | |
-7.64% | 349B | |
+15.00% | 318B | |
+5.99% | 291B | |
+3.51% | 210B | |
-9.65% | 194B | |
-11.71% | 144B | |
-8.32% | 142B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis : Affirms 2040 Net Zero Carbon Targets, Makes Progress on Patient Access Program